Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JG342 is the code name for at least two distinct products depending on context. The primary pharmaceutical context refers to JG342 as an experimental small molecule allosteric inhibitor of HSP70 (heat shock protein 70), researched for its activity against multiple myeloma cell lines, particularly those resistant to proteasome inhibitors like bortezomib. JG342 acts by disrupting the chaperone function of HSP70, perturbing mitochondrial proteostasis and inducing apoptosis in malignant plasma cells. It has shown increased potency compared to related compounds in vitro and some in vivo activity but faces challenges in balancing efficacy and toxicity, especially in murine models. In a medical device context, "JG342" is used to designate a specific silicone clamp or silicone holder (8.5 mm, 5/16”) within Aesculap/B. Braun sterile container surgical supply systems, not a pharmaceutical product[1][7][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on JG342.